Hikma Pharmaceuticals PLC (HIK) - Total Liabilities
Based on the latest financial reports, Hikma Pharmaceuticals PLC (HIK) has total liabilities worth GBX3.00 Billion GBX as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hikma Pharmaceuticals PLC - Total Liabilities Trend (2002–2024)
This chart illustrates how Hikma Pharmaceuticals PLC's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hikma Pharmaceuticals PLC Competitors by Total Liabilities
The table below lists competitors of Hikma Pharmaceuticals PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tajiri Resources Corp
V:TAJ
|
Canada | CA$876.46K |
|
Magna Finance Tbk
JK:MGNA
|
Indonesia | Rp89.47 Billion |
|
FORCS Co.Ltd
KQ:189690
|
Korea | ₩5.51 Billion |
|
Seplat Petroleum Development Company PLC
LSE:SEPL
|
UK | GBX3.22 Billion |
|
HOCHDORF HLDG AG
F:1Z3
|
Germany | €781.00K |
|
SEOJEON ELECTRIC MACHINERY Co.Ltd
KQ:189860
|
Korea | ₩30.48 Billion |
|
Podium Minerals Ltd
AU:POD
|
Australia | AU$1.42 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Hikma Pharmaceuticals PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hikma Pharmaceuticals PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hikma Pharmaceuticals PLC (2002–2024)
The table below shows the annual total liabilities of Hikma Pharmaceuticals PLC from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX2.81 Billion | +13.80% |
| 2023-12-31 | GBX2.47 Billion | +6.37% |
| 2022-12-31 | GBX2.32 Billion | +21.94% |
| 2021-12-31 | GBX1.91 Billion | -4.13% |
| 2020-12-31 | GBX1.99 Billion | +10.33% |
| 2019-12-31 | GBX1.80 Billion | +0.06% |
| 2018-12-31 | GBX1.80 Billion | -3.23% |
| 2017-12-31 | GBX1.86 Billion | -4.71% |
| 2016-12-31 | GBX1.95 Billion | +56.79% |
| 2015-12-31 | GBX1.25 Billion | +20.29% |
| 2014-12-31 | GBX1.03 Billion | +15.64% |
| 2013-12-31 | GBX895.00 Million | +1.44% |
| 2012-12-31 | GBX882.26 Million | +13.55% |
| 2011-12-31 | GBX777.01 Million | +112.58% |
| 2010-12-31 | GBX365.52 Million | +7.68% |
| 2009-12-31 | GBX339.46 Million | -5.04% |
| 2008-12-31 | GBX357.46 Million | -23.84% |
| 2007-12-31 | GBX469.38 Million | +238.77% |
| 2006-12-31 | GBX138.56 Million | +25.41% |
| 2005-12-31 | GBX110.48 Million | +9.06% |
| 2004-12-31 | GBX101.31 Million | +76.52% |
| 2003-12-31 | GBX57.39 Million | +22.54% |
| 2002-12-31 | GBX46.84 Million | -- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more